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ABSTRACT
Several single-institution pilot studies have suggested that augmented preparative regimens, including those containing
total body irradiation combined with an autologous bone marrow transplantation, are superior to standard regimens for
the treatment of relapsed or refractory Hodgkin disease. On the basis of these data, we undertook, in the cooperative
group setting, a phase II trial of augmented preparative regimens for patients experiencing treatment failure with
conventional chemotherapy. Eighty-one patients with either sensitive or refractory (induction failures or chemoresistant)
relapse received etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either total body irradiation (12 Gy) or, if
previously irradiated, carmustine (15 mg/kg), followed by an autologous bone marrow transplantation. Progression-free
(PFS) and overall (OS) survival were estimated, and a Cox regression model was used to assess potential prognostic
variables. The 5-year PFS and OS for the 74 eligible patients treated at 20 Southwest Oncology Group centers were 41%
(95% confidence interval [CI], 29%-53%) and 54% (95% CI, 43%-65%), respectively, despite a median remission after
initial chemotherapy of only 6 months. The 3-year OS for those whose induction therapy failed was 72% (95% CI,
52%-93%). There was 1 (1.4%) early treatment-related death, 2 late deaths due to lung toxicity, and only 1 death due to
myelodysplasia. There were no differences in PFS or OS on the basis of regimen or chemosensitivity. A Cox
prognostic factor analysis determined that >2 prior regimens, relapse in a radiated field, and extranodal disease
were adverse prognostic factors. Among the 46 patients who received prior radiotherapy, the 5-year OS was
38% (95% CI, 14%-61%) for patients with 2 or 3 adverse factors, versus 60% (95% CI, 42%-78%) for those
with 0 factors or 1 adverse factor. Augmented preparative regimens seem promising for the treatment of
relapsed or refractory Hodgkin disease, without an increase in regimen-related mortality. A poor-prognosis
group was identified that should be treated with novel therapies.
© 2003 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Although patients who experience disease pro-
ression or relapse after combination chemotherapy
or Hodgkin disease frequently respond to conven-
ional salvage chemotherapy, few are long-term dis- i
B&MTase-free survivors [1-7]. However, high-dose therapy
ombined with an autologous hematopoietic stem cell
ransplantation after salvage chemotherapy seems to
ncrease the proportion of those who survive disease-
ree [8-15]. This is especially true for patients whoseoi:10.1016/S1083-8791(03)00205-2nduction therapy fails. These patients have little pros-
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pect for long-term progression-free survival (PFS)
with conventional chemotherapy alone [2,5-7,16], but
they have approximately a 40% 5-year overall survival
(OS) after transplantation [17,18].
Less convincing is the potential beneﬁt of trans-
plantation for those who undergo transplantation at
the time of the ﬁrst chemotherapy relapse. These
patients have a 5-year OS of approximately 50% [19-
21]. Although 2 phase III trials comparing conven-
tional chemotherapy versus transplantation for pa-
tients who relapse after a chemotherapy-induced
complete remission (CR) have shown an improved
PFS for those undergoing transplantation [9,10], a
short-term OS beneﬁt for transplant therapy has not
yet been shown. Long-term data from these trials are
lacking. It is indeed possible that longer follow-up
may show a survival advantage for transplantation
(given the higher PFS and long survival after subse-
quent relapse, including those whose autograft fails).
Because of the potential for longer survival with trans-
plantation and because of the increased risk of treat-
ment-related myelodysplasia (MDS) and acute my-
eloid leukemia (AML) after repeated cycles of
conventional chemotherapy/radiotherapy [22-25], it is
generally agreed that a transplantation is appropriate
for patients whose front-line combination chemother-
apy fails. Patients likely to be offered a transplant
are those in poor-risk groups, deﬁned by a short ini-
tial remission duration, chemoresistance at relapse,
poor performance status, B symptoms, 1 extranodal
site at relapse, and increased lactic dehydrogenase
[1-15,17-21].
Given that 60% of patients still relapse after an
autotransplantation, several groups have explored in-
tensifying the preparative regimens. Horning et al.
[26] reported a PFS of 55% at 3 years for patients who
received total body irradiation (TBI) along with both
high-dose etoposide and cyclophosphamide. Nadem-
anee et al. [27] reported 85 patients who received
either the same TBI-based regimen or the same doses
of etoposide and cyclophosphamide with high-dose
carmustine (BCNU; 450 mg/m2) for those who had
received prior radiotherapy. At 28 months, the PFS
rate after transplantation was 52%. Because most re-
lapses after autotransplantations for Hodgkin disease
occur before 2 years, these collective data suggested
that increasing the intensity of preparative regimens
for this disease could improve PFS by 10% to 15%
compared with less-aggressive regimens.
On the basis of these results, a phase II study was
undertaken in the Southwest Oncology Group
(SWOG) for patients who progressed during induc-
tion chemotherapy or relapsed after at least 1 chemo-
therapy-induced remission. This study was modeled
on a similar SWOG study of augmented regimens for
the treatment of relapsed or refractory diffuse aggres-
sive non-Hodgkin lymphoma (NHL) [28]. Given that
chemotherapy sensitivity was identiﬁed as an impor-
tant prognostic factor in phase II trials, patients were
stratiﬁed before transplantation on the basis of che-
motherapy sensitivity. In addition, a multivariate anal-
ysis was undertaken to explore factors associated with
long-term OS.
PATIENTS AND METHODS
Patient Selection
Patients aged 15 to 56 years with relapsed or
refractory Hodgkin disease and who had experienced
treatment failure with at least 1 combination chemo-
therapy regimen were eligible. Those who relapsed
after a previous CR were required to undergo either 2
cycles of salvage chemotherapy or radiotherapy of
localized disease. Salvage therapy was not required for
those whose induction therapy failed, but it was per-
mitted.
Patients were required to have adequate renal
(creatinine clearance 60 mL/min), hepatic (serum
transaminases 3 times the upper limit of normal and
serum bilirubin 2.0 mg/dL), pulmonary (forced ex-
piratory volume in 1 second or diffusion capacity of
carbon monoxide 60% of predicted), and hemato-
logic (white blood cell count 3500/L, hemoglobin
level 10 g/dL, and platelets 100,000/L) function
and histologically normal bone marrow examinations.
In addition, patients must have had a normal cardiac
history and a SWOG performance status of 0 or 1.
Criteria for exclusion included prior hemorrhagic cys-
titis and active infections. All patients were required to
sign a written, informed consent for this trial. The
trial was required to have local institutional review
board approval before implementation.
Patients who had relapsed and responded to sal-
vage chemotherapy were considered to have sensitive
disease, whereas those who either did not enter a CR
with induction chemotherapy or did not have at least
a partial response (PR) to salvage therapy were con-
sidered to have resistant disease. However, patients
who achieved a PR with induction therapy and sub-
sequently responded to salvage chemotherapy were
considered to have chemosensitive disease. Patients
were also classiﬁed by their response to induction
therapy (CR versus less than a CR) and by whether
they received salvage or subsequent therapy. Patients
were further deﬁned retrospectively as having primary
refractory disease if they progressed, had less than a
CR, or relapsed within 6 months after completing the
initial chemotherapy.
Treatment Regimen
Treatment details were essentially identical to
those of our previously reported transplant trial in
diffuse aggressive NHL [28]. Before entry, patients
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underwent a bone marrow harvest under general an-
esthesia. A minimum of 2.0  108 nucleated cells per
kilogram of actual body weight was required to pro-
ceed. Once this was completed, patients underwent
their preparative regimen, as shown in Table 1.
Brieﬂy, patients who had not received a minimum of
2500 cGy of radiation to any ﬁeld were required to
receive the TBI-based transplantation regimen. Pa-
tients received 150 cGy twice a day, separated by a
minimum of 5 hours, for 4 days in the anterior and
posterior positions or by opposing lateral ﬁelds from
days 8 to 5. The dose rate was 5 to 20 cGy/min,
and the fractions were separated by a minimum of 5
hours. The lungs were shielded anterior/posterior and
posterior/anterior for the ﬁnal 600 cGy in all patients
by using standard (5 half-value layer) lung blocks.
The dose was calculated at the midplane and central
axis. Thermoluminescent dosimeters were used at the
ﬁrst dose, and compensators were allowed to keep the
dose in homogeneity at 10%. Corrections for lung
inhomogeneity were not performed.
On day 4, patients received etoposide as a single
4-hour infusion at a dose of 60 mg/kg based on actual
body weight. No adjustments were made on the basis
of actual body weight. Each patient received 25 mg of
diphenhydramine and hydrocortisone 100 mg intra-
venously before the infusion and 2 hours into the
4-hour infusion for prophylaxis against allergic reac-
tions. On day2, patients received cyclophosphamide
at a dose of 100 mg/kg intravenously over 1 to 2 hours
based on ideal body weight. No adjustment was made
on the basis of body weight over ideal weight calcu-
lations. To prevent hemorrhagic cystitis, patients un-
derwent continuous bladder irrigation during and for
24 hours after the cyclophosphamide infusion. On day
0, patients received their cryopreserved marrow stem
cells. Hematopoietic growth factors were permitted.
For those not eligible to receive TBI, the same
doses of etoposide (day 4) and cyclophosphamide
(day 2) as used in the TBI-based regimen were
administered along with high-dose BCNU. The dose
of BCNU was 15 mg/kg, based on ideal body weight,
and it was administered as a single dose on day 6 in
500 mL of saline over 2 hours. The dose was adjusted,
however, to account for obese patients: 40% of the
patient’s weight that was 15 kg above the ideal body
weight was added to the ideal body weight.
Statistical Considerations
A CR was deﬁned as the disappearance of all
clinical evidence of active tumor for a minimum of 4
weeks. A PR was deﬁned as a 50% decrease in the
sum of the product of diameters of all measurable
lesions for a minimum of 4 weeks. For both CR and
PR, a conﬁrmation assessment was required at least 4
weeks after the ﬁrst determination of response. Pro-
gression was deﬁned as (1) an increase of at least 50%
or 10 cm2 (whichever was smaller) in the sum of the
products of measurable lesions over the smallest sum
observed or (2) the appearance of any new disease.
Patients were considered to be nonresponders if they
did not have a PR or CR. Responses were determined
by examinations, radiographs, and computed tomo-
graphic scans. Gallium scans were not used for re-
sponse measurement. Early mortality was deﬁned as
deaths that occurred within the ﬁrst 50 days after
transplantation (infusion of bone marrow) or approx-
imately 60 days after the preparative regimen began.
Standard SWOG toxicity criteria were used to deﬁne
the toxicities in this trial.
The anticipated accrual goal was 45 patients with
sensitive disease and 45 with resistant disease. Forty-
ﬁve patients is sufﬁcient to estimate response proba-
bilities and survival estimates to within15%. Among
90 total patients, any toxicity occurring with at least
5% probability is likely to be seen once (99% chance).
All eligible patients were included in the analysis of
PFS and OS. PFS was measured from the date of
registration until progression, relapse, or death. OS
was measured from the date of registration until death
from any cause. PFS and OS were estimated by the
method of Kaplan and Meier [29] and were compared
by using the log-rank test statistic [30]. Hazard ratios
for PFS and OS were estimated with the Cox regres-
sion model [31]. All signiﬁcance values reported for
PFS and OS are 2 sided.
Multivariate Analysis
Because a signiﬁcant number of patients relapse
after a transplantation for Hodgkin disease, we under-
took a prognostic factor analysis to develop a prog-
nostic factor scale for use in designing future studies.
We analyzed 14 factors with possible predictive value,
including those suggested by the results of previous
studies (Table 2). Factors with a statistically signiﬁcant
or marginally signiﬁcant (P  .10) effect on OS in
Table 1. Transplantation Regimens
TBI/cyclophosphamide/etoposide
TBI* 150 cGy twice daily, days 8, 7, 6, 5
Etoposide† 60 mg/kg IV over 4 h, day 4
Cyclophosphamide3 100 mg/kg IV over 1 h, day 2
ABMT day 0
BCNU/cyclophosphamide/etoposide
BCNU† 15 mg/kg IV over 1 h, day 6
Etoposide† 60 mg/kg IV over 4 h, day 4
Cyclophosphamide‡ 100 mg/kg IV over 1 h, day 2
ABMT day 0
IV indicates intravenous; ABMT, autologous bone marrow
transplantation.
*Lungs shielded after ﬁrst 600 cGy.
†Based on actual body weight.
‡Based on ideal body weight.
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univariate analysis were considered for inclusion in a
risk model. A forward stepwise Cox regression analysis
identiﬁed factors that remained signiﬁcant predictors
of OS in a multivariate setting. For each patient, the
number of adverse factors was counted, and the num-
ber was subsequently analyzed in Cox regression as an
independent variable.
RESULTS
This study opened in 20 SWOG institutions in
April 1990. A total of 81 patients were enrolled before
the trial was closed in December 1995. Seven patients
were ineligible: 1 began protocol therapy before en-
rollment, 1 had NHL, 1 did not receive the required
salvage therapy before transplantation, and 4 had in-
sufﬁcient prestudy documentation. Of the remaining
74 eligible patients, 47 had sensitive disease and 27
had resistant disease. The study was closed after the
sensitive-disease cohort met its accrual goal.
All 74 eligible patients completed protocol ther-
apy. There were 5 regimen-related protocol devia-
tions: 2 patients received TBI despite prior thoracic
radiotherapy, 1 received the BCNU-based regimen
despite no prior radiotherapy, and 2 received post-
transplantation radiotherapy as consolidation therapy.
All eligible patients were assessable for efﬁcacy and
toxicity.
Patient Characteristics
Patient characteristics are shown in Tables 3 and
4. The median age was 28 years (range, 17-53 years).
Among the 74 eligible patients, the TBI-based pre-
parative regimen was administered to 28 (38%) pa-
tients (15 in the sensitive-disease group and 13 in the
resistant-disease group), whereas the BCNU-based
preparative regimen was administered to 48 (62%)
patients. Forty-seven eligible patients (64%) had sen-
sitive disease, and 27 (36%) had resistant disease.
Eighteen patients (24%) had treatment failure with
their initial induction therapy. The median duration
of initial remission was only 6 months; only 33% had
an initial remission 1 year, and only 7% had an
initial remission 2 years. Thirty-ﬁve percent had
increased lactic dehydrogenase, 63% had B symptoms,
and 28% had pulmonary parenchymal lung disease.
Most patients (59%) received 2 prior chemotherapy
regimens, with 19% receiving 3 and 14% receiving 4
more. The largest-diameter mass at transplantation
was 5 cm in 23% of patients. Among the 46 patients
who received prior radiotherapy, 70% relapsed in at
least 1 of the ﬁelds before transplantation.
Prior Treatment Experience
Among the 74 eligible patients, 7 (9%) received
radiotherapy alone as initial therapy for low-stage dis-
ease (and received chemotherapy only after relapse),
whereas 19 (26%) received combined-modality ther-
apy at diagnosis and 48 (65%) received chemotherapy
alone. Fifty-three patients (72%) received methotrex-
ate, vincristine, procarbazine, and prednisone
(MOPP), MOPP with doxorubicin, bleomycin, and
vinblastine, or similar treatment as induction chemo-
therapy, whereas 10 (14%) received doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD)
alone and 11 (15%) received other regimens. (An
additional 8 patients [11%] received MOPP as sec-
ond- or third-line therapy.) Approximately half re-
ceived a platinum-based regimen as their pretrans-
plantation salvage chemotherapy. In the entire cohort,
19 (26%) had treatment failure with induction therapy
(disease progression or less than a CR); among the 55
patients (74%) who had a CR to induction therapy, 24
(44%) relapsed within 6 months of completing induc-
tion chemotherapy. The 43 patients (19 induction
failures plus 24 induction CRs relapsing within 6
months) in these 2 categories (58%) were considered
to have primary refractory disease.
Patient Outcome
All 74 patients completed their transplantation.
There was only 1 (1.4%) early treatment-related
death, which was due to sepsis. This patient was in the
Table 3. Patient Characteristics
Variable Sensitive Resistant Total
No. registered 53 28 81
Ineligible 6 1 7
Insufficient documentation 3 1 4
Eligible 47 27 74
Median age (y) 30 27 28
Male sex 19 (40%) 14 (52%) 33 (45%)
CR to induction therapy 41 (87%) 15 (56%) 55 (74%)
Induction failure 6 (13%) 12 (44%) 18 (24%)
Salvage therapy 47 (100%) 25 (93%) 72 (97%)
TBI preparation 15 (32%) 13 (48%) 28 (38%)
Table 2. Factors Considered for Multivariate Analysis
Sex
SWOG performance status
Duration of initial chemotherapy process
Number of extranodal sites
Sensitivities
B symptoms
Disease bulk >5 cm
No. of prior chemotherapy regimens
LDH at the hospital
Parenchymal lung disease
Relapse in prior RT field
Induction failures
CR to induction therapy
Preparative regimen
LDH indicates lactic dehydrogenase; RT, radiation.
P. J. Stiff et al.
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sensitive-disease group and received the BCNU-based
preparative regimen. There were 3 (4.2%) other late
treatment-related deaths, all after engraftment and all
in the BCNU group. Two patients died of pulmonary
ﬁbrosis/pneumonitis. One of these patients, who re-
ceived 5 prior chemotherapy regimens (including ni-
trosoureas and bleomycin) and mantle radiotherapy,
died 90 days after transplantation; the other patient,
who received 6 prior regimens and mantle radiother-
apy, died on day 68. The third patient died of treat-
ment-related MDS 25 months after his transplanta-
tion. This patient had received combined-modality
therapy with an alkylating agent–based induction che-
motherapy regimen. To date, there have been no
reports of MDS in the TBI arm and no others in the
BCNU arm.
Twelve patients had no evidence of disease at
transplantation and were therefore not assessable for
response. Of the remainder, 9 had insufﬁcient fol-
low-up data to accurately determine response. These
patients were assumed to be nonresponders. Among
the 39 patients with sensitive disease who were avail-
able for response assessment, the CR rate was 23%
(95% conﬁdence interval [CI], 11%-39%). Among the
23 patients with resistant disease who were available
for response assessment, the CR rate was only 9%
(95% CI, 1%-28%). The most common response in
each group was stable disease (41% and 26%, respec-
tively).
The 5-year PFS and OS values for the entire
group were 41% (95% CI, 29%-53%) and 54% (95%
CI, 43%-65%), respectively. As shown in Figure 1,
the 5-year PFS values for the sensitive and resistant
cohorts were 40% (95% CI: 26%-54%) and 41%
(95% CI: 22%-59%), respectively. As shown in Figure
2, the 5-year OS values for the sensitive and resistant
cohorts were 55% (95% CI, 41%-70%) and 52%
(95% CI, 33%-71%), respectively. Of note, for the 18
patients whose induction chemotherapy failed, the
3-year and 5-year PFS values were 56% (95% CI,
33%-79%) and 44% (95% CI, 21%-67%), respec-
tively, whereas the 3-year and 5-year OS values were
72% (95% CI, 52%-93%) and 61% (95% CI, 39%-
84%), respectively. The 5-year PFS and OS values for
the 9 patients who underwent transplantation in CR
were both 67% (95% CI, 36%-97%). As shown, esti-
mates of 8-year survival continue to show no differ-
ences between the 2 groups. The 5-year PFS for the
TBI-based regimen was 43% (95% CI, 25%-61%),
versus 39% (95% CI, 25%-53%) for the BCNU-
based regimen, whereas the 5-year OS rates were 61%
Figure 1. Progression-free survival based on disease sensitivity.
Table 4. Potential Prognostic Factors for Overall Survival
Variable n %
Univariate
P Value
Sex .39
Male 33 45
Female 41 55
SWOG performance status .63
0 56 76
1 18 24
Duration of initial
remission (mo) .88
<12 49 67
>12 24 33
Median (range) 6 (0.5-102)
No. of extranodal sites* .03
0 58 78
>1 14 22
Disease type .84
Sensitive 47 64
Resistant 27 36
Symptoms .80
A 27 37
B 46 63
Disease bulk >5 cm .20
Yes 17 23
No 56 77
Number of prior
chemotherapy regimens* .007
1 6 8
2 44 59
3 14 19
>4 10 14
LDH .99
Normal 48 65
>1 normal 26 35
Parenchymal lung disease .71
Yes 16 28
No 42 72
Relapse in a prior RT field
(in patients with prior
RT only) .09
Yes 32 70
No 14 30
No RT 26
True induction failure .36
Yes 18 24
No 56 76
Response to induction therapy .10
CR 55 74
Less than CR 19 26
Type of preparative regimen .52
TBI 28 38
BCNU 46 62
LDH indicates lactic dehydrogenase; RT, radiation.
*Analyzed on an ordinal scale.
Autologous BMT for Refractory Hodgkin Disease
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(95% CI, 43%-79%) and 50% (95% CI, 36%-64%),
respectively (Figures 3 and 4). The small numbers
prevent statistical comparisons.
Toxicities
The median time to absolutely neutrophil count
recovery after transplantation to 500/L was day 12
and to platelet recovery 20,000/L was day 15.
Similar to the NHL study previously reported, a sub-
stantial amount of mucositis was seen; however, over-
all, only 5 cases (6.8%) of grade 4 mucositis, pharyn-
gitis, or esophagitis were reported. The overall
incidence of grade 3/4 mucositis was higher in those
who received the TBI regimen (64% versus 15%).
The only other difference in toxicity between the 2
regimens was a higher incidence of grade 3/4 bilirubin
increases in the BCNU arm (17% versus 7%), but no
cases of fatal veno-occlusion were seen in either
group. Apparent differences in these toxicities may be
due to patient selection. In addition to the single death
due to sepsis reported previously, there was only a
single case of grade 4 infection, which resolved with
appropriate antibiotic therapy. There were no cases of
grade 4 pneumonitis, and there was only 1 case of
grade 4 skin toxicity, presumably due to etoposide.
Multivariate Analysis
Of the 14 factors analyzed for OS in univariate
analysis, the number of extranodal sites at transplan-
tation (P  .03) and the number of prior chemother-
apy regimens (P  .007) were signiﬁcant, whereas
relapse in a prior radiation ﬁeld (P .09) and response
to initial or induction therapy (P  .10) were border-
line signiﬁcant (Table 4). Of note, the duration of
initial remission did not predict OS. The 4 signiﬁcant
or borderline signiﬁcant factors were analyzed in a
forward stepwise Cox regression procedure. Two of
the 74 patients had incomplete prognostic data. In the
remaining 72 patients, the number of prior chemo-
therapy regimens, number of extranodal sites, and
relapse in a prior radiation ﬁeld retained at least mar-
ginal signiﬁcance in the multivariate setting (Table 5).
Relapse in a prior radiation ﬁeld was deﬁned only
for the subset of 46 patients who received prior radi-
ation and so was not considered as a risk factor for the
entire cohort of 72 patients. For the entire cohort of
72 patients, only the number of prior chemotherapy
regimens and the number of extranodal sites had pre-
dictive value. Predetermined cutoffs for these 2 factors
(3 prior chemotherapy regimens and 1 extranodal
site) were chosen to deﬁne the adverse risk factors.
Thirty-eight patients (53%) had no risk factors, 29
had 1 risk factor, and 5 had 2 risk factors. The number
of risk factors (0-2) was a signiﬁcant predictor of
survival in a Cox regression model (P  .02). To
summarize the effect, in terms of prognostic groups,
patients with 2 factors were grouped with patients
with 1 risk factor (P  .11). The hazard ratio was 1.76
(95% CI, 0.90-3.43).
A second analysis was performed in the 46 patients
who received prior radiotherapy, in whom relapse in a
prior radiation ﬁeld was also associated with OS. Six
patients (13%) had no factors, 24 (52%) had 1 risk
factor, 13 (28%) had 2 risk factors, and 3 (7%) had all
3 adverse risk factors. The number of risk factors (0-3)
was a signiﬁcant predictor of OS in a Cox regression
model (P  .01). As before, to summarize the effect in
terms of prognostic groups, patients with 0 factors or
1 risk factor were grouped together, as were those
with 2 and 3 risk factors (P  .05). The hazard ratio
was 2.26 (95% CI, 1.01-5.07). Five-year OS estimates
are shown in Figure 5. The 5-year OS for patients
with 0 factors or 1 risk factor was 60% (95% CI,
Figure 2. Overall survival based on disease sensitivity. Figure 4. Overall survival based on preparative regimen.
Figure 3. Progression-free survival based on preparative regimen.
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42%-78%), versus 38% (95% CI, 14%-61%) for
those with 2 or 3 risk factors.
DISCUSSION
This SWOG study was based on 2 pilot studies
that suggested that augmented regimens could be ad-
ministered safely and that survival might be enhanced
by 15% to 20% as compared with conventional pre-
parative regimens [26,27]. This ﬁrst US multicenter
study of transplant therapy in Hodgkin disease found
only a 1.4% early-death rate and a survival and toxicity
similar to those in the pilot studies. Our 3-year OS of
72% (95% CI, 52%-93%) for those whose induction
chemotherapy failed represents the best reported sur-
vival for this group to date and compares favorably to
the 50% rate (95% CI, 39%-60%) recently reported
by the Autologous Blood and Marrow Transplant
Registry (ABMTR) [17]. At 5 years, this group had a
survival of 61% (95% CI, 39%-84%), indicating that
the remissions induced by these regimens are durable.
In addition, similar to the results for the NHL trial
[28], all resistant-disease patients seemed to beneﬁt
from these augmented regimens, with a 52% (95%
CI, 33%-71%) 5-year OS. Because gallium scans were
not used for disease responsiveness after salvage che-
motherapy and because positron emission tomo-
graphic scans were not available at most centers dur-
ing the study, it is possible that some patients we
considered resistant were actually in remission at the
time of transplantation. We believe, however, that this
is unlikely, considering that the median relapse-free
survival after initial chemotherapy for the entire group
was only 6 months. Together, these results suggest
that augmented preparative regimens are indicated in
this patient group, although this conclusion requires a
phase III trial for validation.
We considered these regimens to be augmented
from both a dose and schedule standpoint. For the
TBI regimen, the maximum-tolerated dose of etopo-
side combined with TBI [32] was added to the equivalent
of the maximum-tolerated dose of cyclophosphamide
(100 mg/kg) combined with TBI in a standard cyclo-
phosphamide/TBI regimen. In addition, compared
with the ﬁrst studies of high-dose BCNU, cyclophos-
phamide, and etoposide (VP16; BCV), the BCV reg-
imen tested here used a higher dose of both BCNU
and etoposide [33,34], and all chemotherapy agents
were given as single-bolus doses rather than as pro-
longed infusions or repeated daily doses. The sched-
ule, along with the total dose, of alkylating agents may
be important in antitumor responses [35-37], as vali-
dated by in vitro data of cyclophosphamide analogs
suggesting that single large doses may be superior to
multiple smaller doses given over a prolonged period.
This beneﬁt is possibly due to a progressive shorten-
ing of the area under the curve of the active metabo-
lites of cyclophosphamide seen with a multiple dosing
schedule [35].
Long-term follow-up for this study is out to nearly
10 years, allowing us for the ﬁrst time in this disease to
describe the risk of late relapse. As shown, no late
relapses have been seen in the chemotherapy-sensitive
subgroup after 3.5 years, with only a single relapse
more than 2 years after transplantation. Although late
relapses did occur in the chemotherapy-resistant
group (with 2 relapses beyond 7 years), in general
these data extend results from numerous pilot studies
that found that most relapses occur in the ﬁrst 18
months after transplantation [8-15,17-21,38]. This
suggests that novel transplantation therapies intended
to reduce relapses could be evaluated quickly in phase
Figure 5. Overall survival by number of risk factors: 2 prior
chemotherapy regimens, extranodal disease, and relapse in prior
radiation ﬁeld. Hazard ratio: 2.26 (95% CI, 1.01- 5.07).
Table 5. Results of the Forward Stepwise Cox Regression Procedure (P Values) (N  72 Patients with Complete Data)
Step
Prognostic Factor
No. Prior
Chemotherapy
Regimens
No.
Extranodal
Sites
Relapse in
a Prior
RT Field*
Response to
Induction
Therapy
Step 1: add number of prior chemotherapy regimens (P  .007) .009
Step 2: add number of extranodal sites (P  .03) .02 .05
Step 3: add relapse in prior RT field (P  .09) .06 .03 .07
Step 4: add response to induction therapy (P  .10) .05 .02 .07 .12
RT indicates radiation.
*In patients with prior RT only.
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II trials and pursued or discarded on the basis of
2-year PFS.
Our results seem to verify the utility and safety of
TBI-based preparative regimens for this disease. Al-
though TBI has been suggested in the past as an
etiologic factor in posttransplantation AML and MDS
[39-41], none of the 28 patients who received this
preparative regimen and only 1 patient overall devel-
oped MDS with posttransplantation follow-up times
nearing 10 years, despite the use of MOPP or MOPP/
ABVD before transplantation in all but 13 of the
patients treated here and the use of radiotherapy in
half of our patients. The low rate may be related to the
young age of our patients, although the median age of
our group (28 years) is virtually identical to recent
registry reports for this treatment in this disease from
the ABMTR and the European Bone Marrow Trans-
plantation Group [17,18]. That TBI may not be a
causative factor in the genesis of posttransplanta-
tion AML/MDS is further supported by the recent
ABMTR/National Cancer Institute analysis of post-
transplantation MDS/AML in patients who under-
went autotransplantation for lymphoma, including
Hodgkin disease [42], and ﬂuorescence in situ hybrid-
ization data indicating that post–autologous stem cell
transplantation AML/MDS results from clones de-
tected before transplantation [43]. However, single-
institution studies do indicate the possibility that TBI
might be a contributing factor to the development of
AML/MDS [43-45]. This is certainly plausible given
that involved ﬁeld radiotherapy with chemotherapy
does increase the risk of AML/MDS when used in
standard doses for the treatment of lymphoma, either
alone [46] or followed by an autotransplantation [47].
The adverse prognostic factors identiﬁed in the
multivariate analysis indicate that patients with mul-
tiple relapses and with extranodal disease at transplan-
tation have an inferior transplantation outcome.
These are similar to other multivariate analyses re-
ported in the literature [13,14,17,18,20,21,27,39,48,49].
Not previously described is the ﬁnding that relapse in
a prior radiation ﬁeld, likely a new measure of resistant
disease, was also an independent risk factor. Unlike
other studies, we did not ﬁnd chemoresistance at
transplantation to be an adverse risk factor. This may
be explained by the intensity of the preparative regi-
mens, as described previously, but the determination
of chemosensitivity was made only several weeks after
a second and ﬁnal cycle of salvage chemotherapy; this
was potentially too early to determine a favorable
response to the salvage regimen. In an attempt to
identify a poor-prognostic group in whom to test
novel therapies, we identiﬁed a subgroup of patients
with 2 or all 3 of these adverse factors, who had a
5-year OS of only 38%, indicating that novel ap-
proaches should be targeted for this patient subgroup.
This is similar to other reports that also divided pa-
tients into groups on the basis of the number of
adverse prognostic factors [48,49]. Wheeler et al. [49]
described 3 prognostic groups based on the number of
extranodal sites and additional signiﬁcant prognostic
factors not found to be signiﬁcant in our analysis:
nodular sclerosis histology, abnormal performance
status, short time from diagnosis to transplantation,
and presence of B symptoms at relapse. Survival for
the 3 groups ranged from 82% to 19% and again
suggests that the high-risk patients should be offered
innovative therapies rather than a standard transplan-
tation [49].
Options for improving transplantation outcome
have been limited. In most studies, patients with the
best posttransplantation survival were those who un-
derwent transplantation in CR (67% long-term sur-
vival in our study) [14,38,39]. It is appropriate, then,
to investigate whether increasing the CR rate before
transplantation would improve the outcome for pa-
tients with adverse factors. Multicycle high-dose ther-
apy has recently been tested in this disease on the basis
of this strategy [50-52]. In a recently completed 2-in-
stitution pilot study, 47 patients with poor prognostic
factors (induction failures, relapse 1 year, B symp-
toms, or extranodal disease) received a cycle of high-
dose melphalan at 150 mg/m2 with an autotransplan-
tation before one of the ablative transplantation
regimens used in this study [50]. After a follow-up of
2 years, the PFS and OS rates for the 47 eligible
patients were 64% (95% CI, 48%-79%) and 73%
(95% CI, 38%-68%), respectively; these are higher
than the estimates obtained in this study and other
studies in the literature. On the basis of these favor-
able data and those of other tandem approaches [51-
53], SWOG plans to initiate a groupwide phase II
study of this tandem transplantation approach.
Another strategy for the poor-prognosis group
would be to explore allogeneic transplantation. Al-
though there seems to be a graft-versus–Hodgkin dis-
ease effect, studies performed in the late 1980s and
1990s that used ablative preparative regimens had a
dismal outcome, with a 70% incidence of treatment-
related mortality [54-57]. With the early success of
submyeloablative approaches in reducing regimen-re-
lated toxicities in low-grade leukemia and lymphoma,
Cooney et al. [58] tested BCNU, etoposide, cytara-
bine, and melphalan chemotherapy with either a re-
lated or an unrelated allograft in 10 patients who had
experienced treatment failure with a previous au-
tograft for Hodgkin disease. They recently reported a
0% 100-day mortality and an estimated 2-year PFS of
65% [58]. These preliminary data will need to be
veriﬁed, ideally in a multicenter setting. If PFS is
favorable, other trials will need to determine the exact
timing of this therapy. However, the favorable pilot
data on tandem transplantations for patients with
high-risk disease and these preliminary allograft data
P. J. Stiff et al.
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suggest that allografts should be reserved currently for
patients who relapse after an autograft.
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